Cargando…
A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder?
There have been many advancements in the field of neuromyelitis optica and neuromyelitis optica spectrum disorder since the discovery of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibodies. It is also recognized that the pathological features associated with myelin oligodendrocyte...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423626/ https://www.ncbi.nlm.nih.gov/pubmed/37581199 http://dx.doi.org/10.7759/cureus.43428 |
_version_ | 1785089492744404992 |
---|---|
author | Aylia, Fatin Johri, Karn Spencer, Riley Chu, David Deriss, Mehron Peng, Davin Eskenazi, Jonathan Liu, Antonio K |
author_facet | Aylia, Fatin Johri, Karn Spencer, Riley Chu, David Deriss, Mehron Peng, Davin Eskenazi, Jonathan Liu, Antonio K |
author_sort | Aylia, Fatin |
collection | PubMed |
description | There have been many advancements in the field of neuromyelitis optica and neuromyelitis optica spectrum disorder since the discovery of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibodies. It is also recognized that the pathological features associated with myelin oligodendrocyte glycoprotein antibodies are beyond the domain of neuromyelitis optica spectrum disorder and there is a separate nomenclature, namely myelin oligodendrocyte glycoprotein antibody associated disease. Currently, there is no aquaporin-4 antibody associated disorder, even though aquaporin-4 antibodies are not as widely present in other disorders. Miller Fisher syndrome (MFS) is a variant of Guillain Barré syndrome, in which there are positive GQ1b antibodies with no evidence of myelitis or optic neuritis. MFS is not considered a component of neuromyelitis optica spectrum disorder. We report on a patient with MFS that was positive for GQ1b and aquaporin-4 antibodies but negative for myelin oligodendrocyte glycoprotein antibodies and is devoid of any features of neuromyelitis optica spectrum disorder. This finding may lead to investigations and reports of other pathologies that are associated with the aquaporin-4 antibody. |
format | Online Article Text |
id | pubmed-10423626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-104236262023-08-14 A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder? Aylia, Fatin Johri, Karn Spencer, Riley Chu, David Deriss, Mehron Peng, Davin Eskenazi, Jonathan Liu, Antonio K Cureus Neurology There have been many advancements in the field of neuromyelitis optica and neuromyelitis optica spectrum disorder since the discovery of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibodies. It is also recognized that the pathological features associated with myelin oligodendrocyte glycoprotein antibodies are beyond the domain of neuromyelitis optica spectrum disorder and there is a separate nomenclature, namely myelin oligodendrocyte glycoprotein antibody associated disease. Currently, there is no aquaporin-4 antibody associated disorder, even though aquaporin-4 antibodies are not as widely present in other disorders. Miller Fisher syndrome (MFS) is a variant of Guillain Barré syndrome, in which there are positive GQ1b antibodies with no evidence of myelitis or optic neuritis. MFS is not considered a component of neuromyelitis optica spectrum disorder. We report on a patient with MFS that was positive for GQ1b and aquaporin-4 antibodies but negative for myelin oligodendrocyte glycoprotein antibodies and is devoid of any features of neuromyelitis optica spectrum disorder. This finding may lead to investigations and reports of other pathologies that are associated with the aquaporin-4 antibody. Cureus 2023-08-13 /pmc/articles/PMC10423626/ /pubmed/37581199 http://dx.doi.org/10.7759/cureus.43428 Text en Copyright © 2023, Aylia et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Neurology Aylia, Fatin Johri, Karn Spencer, Riley Chu, David Deriss, Mehron Peng, Davin Eskenazi, Jonathan Liu, Antonio K A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder? |
title | A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder? |
title_full | A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder? |
title_fullStr | A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder? |
title_full_unstemmed | A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder? |
title_short | A Patient With Miller Fisher Syndrome With Positive GQ1b and Aquaporin-4 Antibodies: Will There Be an Aquaporin-4 Antibody Associated Disorder? |
title_sort | patient with miller fisher syndrome with positive gq1b and aquaporin-4 antibodies: will there be an aquaporin-4 antibody associated disorder? |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423626/ https://www.ncbi.nlm.nih.gov/pubmed/37581199 http://dx.doi.org/10.7759/cureus.43428 |
work_keys_str_mv | AT ayliafatin apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT johrikarn apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT spencerriley apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT chudavid apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT derissmehron apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT pengdavin apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT eskenazijonathan apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT liuantoniok apatientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT ayliafatin patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT johrikarn patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT spencerriley patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT chudavid patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT derissmehron patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT pengdavin patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT eskenazijonathan patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder AT liuantoniok patientwithmillerfishersyndromewithpositivegq1bandaquaporin4antibodieswilltherebeanaquaporin4antibodyassociateddisorder |